272 related articles for article (PubMed ID: 11123995)
1. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
Burnouf C; Auclair E; Avenel N; Bertin B; Bigot C; Calvet A; Chan K; Durand C; Fasquelle V; Féru F; Gilbertsen R; Jacobelli H; Kebsi A; Lallier E; Maignel J; Martin B; Milano S; Ouagued M; Pascal Y; Pruniaux MP; Puaud J; Rocher MN; Terrasse C; Wrigglesworth R; Doherty AM
J Med Chem; 2000 Dec; 43(25):4850-67. PubMed ID: 11123995
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indoles: novel PDE4 inhibitors.
Pascal Y; Andrianjara CR; Auclair E; Avenel N; Bertin B; Calvet A; Féru F; Lardon S; Moodley I; Ouagued M; Payne A; Pruniaux MP; Szilagyi C
Bioorg Med Chem Lett; 2000 Jan; 10(1):35-8. PubMed ID: 10636238
[TBL] [Abstract][Full Text] [Related]
4. 7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as novel inhibitors of human eosinophil phosphodiesterase.
Duplantier AJ; Andresen CJ; Cheng JB; Cohan VL; Decker C; DiCapua FM; Kraus KG; Johnson KL; Turner CR; UmLand JP; Watson JW; Wester RT; Williams AS; Williams JA
J Med Chem; 1998 Jun; 41(13):2268-77. PubMed ID: 9632360
[TBL] [Abstract][Full Text] [Related]
5. Aryl sulfonamides as selective PDE4 inhibitors.
Montana JG; Buckley GM; Cooper N; Dyke HJ; Gowers L; Gregory JP; Hellewell PG; Kendall HJ; Lowe C; Maxey R; Miotla J; Naylor RJ; Runcie KA; Tuladhar B; Warneck JB
Bioorg Med Chem Lett; 1998 Oct; 8(19):2635-40. PubMed ID: 9873594
[TBL] [Abstract][Full Text] [Related]
6. 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
Christensen SB; Guider A; Forster CJ; Gleason JG; Bender PE; Karpinski JM; DeWolf WE; Barnette MS; Underwood DC; Griswold DE; Cieslinski LB; Burman M; Bochnowicz S; Osborn RR; Manning CD; Grous M; Hillegas LM; Bartus JO; Ryan MD; Eggleston DS; Haltiwanger RC; Torphy TJ
J Med Chem; 1998 Mar; 41(6):821-35. PubMed ID: 9526558
[TBL] [Abstract][Full Text] [Related]
7. Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-Asthmatics.
Kim E; Chun HO; Jung SH; Kim JH; Lee JM; Suh BC; Xiang MX; Rhee CK
Bioorg Med Chem Lett; 2003 Jul; 13(14):2355-8. PubMed ID: 12824033
[TBL] [Abstract][Full Text] [Related]
8. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB
J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
[TBL] [Abstract][Full Text] [Related]
9. CDP840. A prototype of a novel class of orally active anti-inflammatory phosphodiesterase 4 inhibitors.
Alexander RP; Warrellow GJ; Eaton MA; Boyd EC; Head JC; Porter JR; Brown JA; Reuberson JT; Hutchinson B; Turner P; Boyce B; Barnes D; Mason B; Cannell A; Taylor RJ; Zomaya A; Millican A; Leonard J; Morphy R; Wales M; Perry M; Allen RA; Gozzard N; Hughes B; Higgs G
Bioorg Med Chem Lett; 2002 Jun; 12(11):1451-6. PubMed ID: 12031318
[TBL] [Abstract][Full Text] [Related]
10. Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.
Ukita T; Sugahara M; Terakawa Y; Kuroda T; Wada K; Nakata A; Ohmachi Y; Kikkawa H; Ikezawa K; Naito K
J Med Chem; 1999 Mar; 42(6):1088-99. PubMed ID: 10090791
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and cyclic AMP phosphodiesterase 4 isoenzyme inhibitory activity of heterocycle condensed purines.
Suzuki H; Yamamoto M; Shimura S; Miyamoto K; Yamamoto K; Sawanishi H
Chem Pharm Bull (Tokyo); 2002 Sep; 50(9):1163-8. PubMed ID: 12237530
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of a novel series of phosphodiesterase IV inhibitors. A potential treatment for asthma.
Beasley SC; Cooper N; Gowers L; Gregory JP; Haughan AF; Hellewell PG; Macari D; Miotla J; Montana JG; Morgan T; Naylor R; Runcie KA; Tuladhar B; Warneck JB
Bioorg Med Chem Lett; 1998 Oct; 8(19):2629-34. PubMed ID: 9873593
[TBL] [Abstract][Full Text] [Related]
13. 7-Methoxyfuro[2,3-c]pyridine-4-carboxamides as PDE4 inhibitors: a potential treatment for asthma.
Buckley GM; Cooper N; Davenport RJ; Dyke HJ; Galleway FP; Gowers L; Haughan AF; Kendall HJ; Lowe C; Montana JG; Oxford J; Peake JC; Picken CL; Richard MD; Sabin V; Sharpe A; Warneck JB
Bioorg Med Chem Lett; 2002 Feb; 12(3):509-12. PubMed ID: 11814830
[TBL] [Abstract][Full Text] [Related]
14. N-arylrolipram derivatives as potent and selective PDE4 inhibitors.
Bacher E; Boer C; Bray-French K; Demnitz FW; Keller TH; Mazzoni L; Müller T; Walker C
Bioorg Med Chem Lett; 1998 Nov; 8(22):3229-34. PubMed ID: 9873708
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative, with anti-inflammatory activities.
Trifilieff A; Wyss D; Walker C; Mazzoni L; Hersperger R
J Pharmacol Exp Ther; 2002 Apr; 301(1):241-8. PubMed ID: 11907180
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of neutrophilic inflammation inhibitors.
Bruno O; Brullo C; Arduino N; Schenone S; Ranise A; Bondavalli F; Ottonello L; Dapino P; Dallegri F
Farmaco; 2004 Mar; 59(3):223-35. PubMed ID: 14987986
[TBL] [Abstract][Full Text] [Related]
17. Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity.
Ahn HS; Bercovici A; Boykow G; Bronnenkant A; Chackalamannil S; Chow J; Cleven R; Cook J; Czarniecki M; Domalski C; Fawzi A; Green M; Gündes A; Ho G; Laudicina M; Lindo N; Ma K; Manna M; McKittrick B; Mirzai B; Nechuta T; Neustadt B; Puchalski C; Pula K; Zhang H
J Med Chem; 1997 Jul; 40(14):2196-210. PubMed ID: 9216839
[TBL] [Abstract][Full Text] [Related]
18. Substituted furans as inhibitors of the PDE4 enzyme.
Perrier H; Bayly C; Laliberté F; Huang Z; Rasori R; Robichaud A; Girard Y; Macdonald D
Bioorg Med Chem Lett; 1999 Feb; 9(3):323-6. PubMed ID: 10091677
[TBL] [Abstract][Full Text] [Related]
19. Discovery of new orally active phosphodiesterase (PDE4) inhibitors.
Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
Chem Pharm Bull (Tokyo); 2004 Sep; 52(9):1098-104. PubMed ID: 15340197
[TBL] [Abstract][Full Text] [Related]
20. Quaternary substituted PDE4 inhibitors I: the synthesis and in vitro evaluation of a novel series of oxindoles.
Hulme C; Poli GB; Huang FC; Souness JE; Djuric SW
Bioorg Med Chem Lett; 1998 Jan; 8(2):175-8. PubMed ID: 9871649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
